Skip to main content
Premium Trial:

Request an Annual Quote

Daniel O Day, Heiner Dreismann, Applied Biosystems, CombiMatrix

Premium

Pairings

Daniel O'Day has replaced Heiner Dreismann as head of Roche Molecular Diagnostics, Roche said last week. O'Day most recently served as head of operations for Roche Pharmaceuticals in Denmark.

As head of Roche Molecular Diagnostics, O'Day will be responsible for all global functions including research, development, manufacturing, and marketing, as well as site operations in Pleasanton and Alameda, Calif.; Branchburg and Belleville, NJ; and Penzberg, Germany.

O'Day holds a BS in biology from Georgetown University and an MBA from Columbia University.

 

New Releases

Applied Biosystems last week launched its TargetSeq Resequencing System, which is intended for resequencing smaller genomes and targeted genomic regions using the company's 3730 and 3730xl DNA Analyzers. The TargetSeq system includes a software module for sequencing small DNA stretches of 200 to 400 bases in 20 minutes or less, the company said. The system increases the number of bases read by the 3730 Analyzer to more than 2.8 megabases per day, the company added.


CombiMatrix this week launched upgraded versions of its CustomArray and CustomArray Synthesizer that enable users to synthesize the firm's CustomArray 90K, an array that can contain up to 94,000 features.

Filed under

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.